Trémeau

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

Retrieved on: 
Thursday, July 20, 2023

has been appointed to the Company’s Board of Directors, effective July 18 2023.

Key Points: 
  • has been appointed to the Company’s Board of Directors, effective July 18 2023.
  • “We are pleased to welcome Mark to Trevena’s Board of Directors,” said Carrie Bourdow, Trevena’s President and CEO.
  • “Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise.
  • Dr. Corrigan serves as Chairman of the Board of Directors of Elios Therapeutics and as a member of the Board of Directors of Nabriva Therapeutics and Wave Life Sciences.

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Retrieved on: 
Friday, November 11, 2022

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.

Key Points: 
  • Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.
  • These patients are often left with the inadequate options of living with pain, or resorting to opioids for pain relief.
  • Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs, Dr. Boice added.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005054/en/

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th

Retrieved on: 
Thursday, October 20, 2022

Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.

Key Points: 
  • Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.
  • In addition, Tremeaus Founder and CEO Bradford C. Sippy will discuss the companys development pipeline, including Phase III-ready TRM-201 (rofecoxib).
  • Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine.
  • Tremeaus lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.

Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)

Retrieved on: 
Tuesday, June 14, 2022

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Key Points: 
  • Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
  • Previously marketed as VIOXX, rofecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile in multiple indications, including acute migraine.
  • Tremeau expects that the development program for TRM-201 will include one Phase III acute efficacy and safety study in migraine.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.

Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders

Retrieved on: 
Monday, December 13, 2021

Both online-only presentations were published in ASHs November supplemental issue of Blood.

Key Points: 
  • Both online-only presentations were published in ASHs November supplemental issue of Blood.
  • TRM-201 is an investigational non-opioid pain treatment containing rofecoxib.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005007/en/

Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain

Retrieved on: 
Monday, October 25, 2021

Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Key Points: 
  • Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
  • These studies suggest that TRM-362 could provide similar or greater acute pain efficacy when compared to non-enriched etoricoxib, potentially at a lower dose.
  • The surgical community would welcome a more potent non-opioid pain medication that does not carry the bleeding risk of traditional NSAIDs.
  • We will work proactively with FDA to design a product for acute pain that ensures access only for short-term use.